COMMUNIQUÉS West-GlobeNewswire

Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
04/02/2026
February 4, 2026 Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – [...]
Revolo to Present at the 2026 AAAAI Annual Meeting
04/02/2026
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics Limited (“Revolo”) today announced that it will present a poster on its lead candidate, IRL201104 (‘1104), at the [...]
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
04/02/2026
MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor
04/02/2026
Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051 DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” [...]
R1 Awarded ‘Best in KLAS’ Across Multiple RCM Categories for 2026
04/02/2026
Providers Recognize R1 for Unwavering Commitment to Launching Innovative Technology CHICAGO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), the leader in healthcare revenue management, has been named a [...]
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
04/02/2026
Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-Delivery MOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE [...]
NewGen and Evident Capital Successfully Activate Commitment Campaign for Inaugural Tokenized Real Estate Bond, Delivering on Cross-Border Real World Asset Financing Strategy
04/02/2026
Rapid progress from announcement of successful launch in under two weeks signals NewGen’s expertise and commitment Launch represents fulfilment of NewGen’s goals to spearhead Real World Asset tokenization, puts Company [...]
Balt’s Squid™ Liquid Embolic Receives FDA Approval for Adjunctive Treatment for Patients with Chronic Subdural Hematomas
04/02/2026
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is approved for the [...]
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
04/02/2026
This is the third program that successfully combines Entera’s oral peptide N-Tab ® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an [...]
CytomX Therapeutics to Present at Upcoming February Conferences
04/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Stryker declares an $0.88 per share quarterly dividend
04/02/2026
Portage, Michigan, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable April 30, 2026, to shareholders of record at the [...]
Cozeva Earns 2026 Best in KLAS for Risk Adjustment: POC and In-Home Health Assessments
04/02/2026
SAN RAMON, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Cozeva, a healthcare technology company delivering a single, unified platform for value-based care, has earned the 2026 Best in KLAS distinction for Risk Adjustment: [...]
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
04/02/2026
CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
04/02/2026
NAARDEN, The Netherlands and MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism
04/02/2026
This is the third program that s uccessfully combine s Entera’s oral peptide N- Tab ® platform with OPKO ’s advanced protein chemistry capabilities The c ompanies have accelerated this program and aim to file an [...]
Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™
04/02/2026
Two-year follow-up data demonstrate sustained benefit, including improvements in pain, fatigue and bone health, following single low dose of avigbagene parvec (FLT201) Robust improvements in lyso-Gb1, a surrogate [...]
‘Think Mortgage Calculator, But for Lung Cancer Risk’: A More User-Friendly Self-Serve Tool Gives Canadians and Healthcare Providers a Clearer Starting Point
04/02/2026
A simple online tool offered by Lung Health Foundation helps people understand their potential lung cancer risk – no medical knowledge, paperwork or special access required TORONTO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- [...]
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
04/02/2026
Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersen The high-dose regimen of [...]
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™
04/02/2026
Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients CELEBRATION, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra [...]

Pages